The effectiveness of immune checkpoint blockade therapy demonstrates that melanoma cells express antigens that can be recognized by CD4 and CD8 T cells, and also that T cell responses to those antigens can mediate tumor regression, when tumor-associated immune dysfunction is abrogated. The gene discussed is CD8A; the disease is neoplasm.